CN107405406A - 用于治疗肺纤维化的血管紧张素ii受体激动剂 - Google Patents

用于治疗肺纤维化的血管紧张素ii受体激动剂 Download PDF

Info

Publication number
CN107405406A
CN107405406A CN201680012711.8A CN201680012711A CN107405406A CN 107405406 A CN107405406 A CN 107405406A CN 201680012711 A CN201680012711 A CN 201680012711A CN 107405406 A CN107405406 A CN 107405406A
Authority
CN
China
Prior art keywords
composition
receptor
angiotensin
pulmonary fibrosis
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201680012711.8A
Other languages
English (en)
Chinese (zh)
Inventor
B·达勒夫
A·永格伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of CN107405406A publication Critical patent/CN107405406A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680012711.8A 2015-03-02 2016-03-02 用于治疗肺纤维化的血管紧张素ii受体激动剂 Withdrawn CN107405406A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126880P 2015-03-02 2015-03-02
US62/126,880 2015-03-02
PCT/GB2016/050552 WO2016139475A1 (en) 2015-03-02 2016-03-02 Angiotensin ii receptor agonist for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
CN107405406A true CN107405406A (zh) 2017-11-28

Family

ID=55646777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680012711.8A Withdrawn CN107405406A (zh) 2015-03-02 2016-03-02 用于治疗肺纤维化的血管紧张素ii受体激动剂

Country Status (11)

Country Link
US (1) US20180078529A1 (enExample)
EP (1) EP3265082A1 (enExample)
JP (1) JP2018507244A (enExample)
KR (1) KR20170122754A (enExample)
CN (1) CN107405406A (enExample)
AU (1) AU2016227486A1 (enExample)
BR (1) BR112017018715A2 (enExample)
CA (1) CA2977445A1 (enExample)
HK (1) HK1244232A1 (enExample)
MX (1) MX2017010993A (enExample)
WO (1) WO2016139475A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213019A1 (zh) * 2022-05-05 2023-11-09 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204163A1 (ja) * 2016-05-23 2017-11-30 国立研究開発法人国立循環器病研究センター 肺障害の予防または抑制用医薬
WO2019014710A1 (en) * 2017-07-17 2019-01-24 Monash University ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF
WO2019238962A1 (en) 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
GB201917327D0 (en) 2019-11-28 2020-01-15 Vicore Pharma Ab New pharmaceutical use
CA3175559A1 (en) 2020-03-19 2021-09-23 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US11123329B1 (en) 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202007122D0 (en) 2020-05-14 2020-07-01 Vicore Pharma Ab New process
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
US20240262813A1 (en) 2021-07-09 2024-08-08 Vicore Pharma Ab New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
EP4467156A4 (en) * 2022-01-21 2025-10-01 Univ Nagasaki PHARMACEUTICAL COMPOSITION FOR INHIBITING ORGAN FIBROSIS
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
IE20230600A3 (en) * 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
EP4648850A1 (en) 2023-01-09 2025-11-19 Vicore Pharma AB Selective angiotensin ii compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
EP1395566B1 (en) 2001-05-31 2007-09-12 Vicore Pharma AB Tricyclic compounds useful as angiotensin ii agonists
US8835471B2 (en) * 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2832357A1 (en) * 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213019A1 (zh) * 2022-05-05 2023-11-09 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法

Also Published As

Publication number Publication date
BR112017018715A2 (pt) 2018-04-17
US20180078529A1 (en) 2018-03-22
CA2977445A1 (en) 2016-09-09
JP2018507244A (ja) 2018-03-15
AU2016227486A1 (en) 2017-08-17
MX2017010993A (es) 2018-04-11
HK1244232A1 (zh) 2018-08-03
KR20170122754A (ko) 2017-11-06
EP3265082A1 (en) 2018-01-10
WO2016139475A1 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
CN107405406A (zh) 用于治疗肺纤维化的血管紧张素ii受体激动剂
JP6097888B2 (ja) 新規使用
JP2024159910A (ja) Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用
JP2005532330A5 (enExample)
KR20130105741A (ko) 디펩티딜 펩티다제 ⅳ 억제제의 용도
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
KR20050042154A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물
CN116726178A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
JP7640474B2 (ja) 血管性浮腫の治療
EP4125937A1 (en) Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
ZA200503542B (en) Pharmaceutical combination of telmisartan and atovastatin for the prophylaxis of treatment of cardiovascular, cardiopulmonary, pulmanory or renal diseases
WO2017006254A1 (en) Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
AU766453C (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
Yu et al. Pirfenidone improves early cardiac function following myocardial infarction by enhancing the elastin/collagen ratio
WO2016193883A1 (en) Sacubitril and valsartan for treating metabolic disease
WO2019183513A1 (en) Compositions and methods for the treatment and prevention of muscular dystrophy
CN115916208A (zh) 用于治疗肌肉萎缩症的方法和组合物
US20250312332A1 (en) Treatment of muscle fibrosis
WO2023107611A1 (en) Methods and compositions for the treatment or prevention of muscular dystrophy
WO2022182547A1 (en) Heteroaryl derivatives as apelin receptor agonists
TW202400145A (zh) 治療ｓ１ｐ受體相關病況之方法
CN101361736A (zh) 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方
HK40085850A (en) Methods and compositions for the treatment of muscular dystrophy
RU2385723C2 (ru) Применение ингибиторов дипептидилпептидазы iv
Maggioni et al. β-Adrenoceptor antagonists and antianginal drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20171128